Julio M. Pow-Sang, MD

Where You Are:

Julio M. Pow-Sang, MD


For Consultation Requests or Referrals: (813) 745-8418


          •  Urology

          •  University of Florida College of Medicine - Urologic Oncology

          •  University of Miami School of Medicine - Urology
          •  University of Miami School of Medicine - General Surgery

          •  University Autonoma De Guadalajara, Mexico - MD

  • Luchey AM, Agarwal G, Espiritu PN, Lockhart JL, Pow-Sang JM, Spiess PE, Sexton WJ, Poch MA. Patient and disease-specific factors and their influence on urinary reconstruction choice at a referral center. World J Urol. 2015 Mar. Pubmedid: 25774005.

  • Quinn GP, Block RG, Clayman ML, Kelvin J, Arvey SR, Lee JH, Reinecke J, Sehovic I, Jacobsen PB, Reed D, Gonzalez L, Vadaparampil ST, Laronga C, Lee MC, Pow-Sang J, Eggly S, Franklin A, Shah B, Fulp WJ, Hayes-Lattin B. If you did not document it, it did not happen: rates of documentation of discussion of infertility risk in adolescent and young adult oncology patients' medical records. J Oncol Pract. 2015 Mar;11(2):137-144. Pubmedid: 25549654.

  • Zargar-Shoshtari K, Sharma P, Espiritu P, Kurian T, Pow-Sang JM, Mangar D, Sexton WJ, Spiess PE. Caval tumor thrombus volume influences outcomes in renal cell carcinoma with venous extension. Urol Oncol. 2015 Mar;33(3):112.e23-112.e29. Pubmedid: 25555854.

  • Sharma P, Zargar-Shoshtari K, Caracciolo JT, Richard GJ, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE. Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection. World J Urol. 2015 Jan. Pubmedid: 25552207.

  • Gopman JM, Djajadiningrat RS, Baumgarten AS, Espiritu PN, Horenblas S, Zhu Y, Protzel C, Pow-Sang JM, Kim T, Sexton WJ, Poch MA, Spiess PE. Predicting postoperative complications of inguinal lymph node dissection for penile cancer in an international multicentre cohort. BJU Int. 2014 Dec. Pubmedid: 25777366.

  • Gallaher J, Cook LM, Gupta S, Araujo A, Dhillon J, Park JY, Scott JG, Pow-Sang J, Basanta D, Lynch CC. Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling. Clin Exp Metastas. 2014 Dec;31(8):991-999. Pubmedid: 25173680.

  • Davis SN, Sutton SK, Vadaparampil ST, Meade CD, Rivers BM, Patel MV, Torres-Roca JF, Heysek RV, Spiess P, Pow-Sang J, Jacobsen PB, Gwede CK. Informed decision making among first-degree relatives of prostate cancer survivors: A pilot randomized trial. Contemp Clin Trials. 2014 Nov;39(2):327-334. Pubmedid: 25465497. Pmcid: PMC4274628.

  • Baumgarten AS, Alhammali E, Hakky TS, Espiritu PN, Pow-Sang JM, Sexton WJ, Lockhart JL, Protzel C, Hakenberg O, Muneer A, Spiess PE. Salvage surgical resection for isolated locally recurrent inguinal lymph node metastasis of penile cancer: international study collaboration. J Urol. 2014 Sep;192(3):760-764. Pubmedid: 24603104.

  • Carastro LM, Lin HY, Park HY, Kim D, Radlein S, Hampton KK, Hakam A, Zachariah B, Pow-Sang J, Park JY. Role of p73 Dinucleotide Polymorphism in Prostate Cancer and p73 Protein Isoform Balance. Prostate Cancer. 2014 Aug;2014:129582. Pubmedid: 25097786. Pmcid: PMC4109114.

  • Russell CM, Espiritu PN, Kassouf W, Schwaab T, Buethe DD, Dhilon J, Sexton WJ, Poch M, Powsang JM, Tanguay S, Nayan M, Alsaadi H, Hanzly MI, Spiess PE. Surgical outcomes in the management of isolated nodal recurrences: a multicenter, international retrospective cohort. J Urol. 2014 Aug;192(2):350-356. Pubmedid: 24530987.

  • Espiritu PN, Sverrisson EF, Sexton WJ, Pow-Sang JM, Poch MA, Dhillon J, Spiess PE. Effect of tumor size on recurrence-free survival of upper tract urothelial carcinoma following surgical resection. Urol Oncol. 2014 Jul;32(5):619-624. Pubmedid: 24495448.

  • Sverrisson EF, Kim T, Espiritu PN, Sexton WJ, Pow-Sang JM, Dhillon J, Spiess PE. The merits of cytology in the workup for upper tract urothelial carcinoma - a contemporary review of a perplexing issue. Int Braz J Urol. 2014 Jul;40(4):493-498. Pubmedid: 25251966.

  • Gwede CK, Davis SN, Wilson S, Patel M, Vadaparampil ST, Meade CD, Rivers BM, Yu D, Torres-Roca J, Heysek R, Spiess PE, Pow-Sang J, Jacobsen P. Perceptions of Prostate Cancer Screening Controversy and Informed Decision Making: Implications for Development of a Targeted Decision Aid for Unaffected Male First-Degree Relatives. Am J Health Promot. 2014 Jun. Pubmedid: 24968183. Pmcid: PMC4277494.

  • Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M. Prostate cancer, version 2.2014. J Natl Compr Canc Ne. 2014 May;12(5):686-718. Pubmedid: 24812137.

  • Strom TJ, Wilder RB, Fernandez DC, Mellon EA, Saini AS, Hunt DC, Pow-Sang JM, Spiess PE, Sexton WJ, Poch MA, Biagioli MC. A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy?intensity modulated radiation therapy. Radiother Oncol. 2014 Apr;111(1):126-131. Pubmedid: 24746567.

  • Sverrisson EF, Nguyen H, Kim T, Pow-Sang JM. Primary cryosurgery for clinically localized prostate cancer--do perioperative tumor characteristics correlate with post-treatment biopsy results?. Urology. 2014 Feb;83(2):376-378. Pubmedid: 24315311.

  • Chornokur G, Amankwah EK, Davis SN, Phelan CM, Park JY, Pow-Sang J, Kumar NB. Variation in HNF1B and Obesity May Influence Prostate Cancer Risk in African American Men: A Pilot Study. Prostate Cancer. 2014 Jan;2013:384594. Pubmedid: 24386569. Pmcid: PMC3872424.

  • Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M. Prostate cancer, version 1.2014. J Natl Compr Canc Ne. 2013 Dec;11(12):1471-1479. Pubmedid: 24335682.

  • Sverrisson E, Jones JS, Pow-Sang JM. Cryosurgery for prostate cancer: a comprehensive review. Arch Esp Urol. 2013 Jul;66(6):546-556. Pubmedid: 23985454.

  • Pow-Sang JM. The improving landscape of urologic oncology. Cancer Control. 2013 Jul;20(3):158-159. Pubmedid: 23811699.

  • Nguyen HD, Allen BJ, Pow-Sang JM. Focal cryotherapy in the treatment of localized prostate cancer. Cancer Control. 2013 Jul;20(3):177-180. Pubmedid: 23811701.

  • Chornokur G, Han G, Tanner R, Lin HY, Green BL, Pow-Sang J, Phelan CM. High grade prostate intraepithelial neoplasia (PIN) is a PSA-independent risk factor for prostate cancer in African American men: results from a pilot study. Cancer Lett. 2013 May;331(2):154-157. Pubmedid: 23268329. Pmcid: PMC3603576.

  • Amankwah EK, Anegbe E, Park H, Pow-Sang J, Hakam A, Park JY. miR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases. Asian J Androl. 2013 Mar;15(2):226-230. Pubmedid: 23353719. Pmcid: PMC3705740.

  • Rao SR, Correa JJ, Sexton WJ, Pow-Sang JM, Dickinson SI, Lin HY, Spiess PE. Prospective clinical trial of the feasibility and safety of modified retroperitoneal lymph node dissection at time of nephroureterectomy for upper tract urothelial carcinoma. BJU Int. 2012 Dec;110(11 pt B):E475-E480. Pubmedid: 22564727.

  • Spiess PE, Kurian T, Lin HY, Rawal B, Kim T, Sexton WJ, Pow-Sang JM. Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy. BJU Int. 2012 Dec;110(11 pt B):E470-E474. Pubmedid: 22519938.

  • Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Sep;10(9):1081-1087. Pubmedid: 22956807.

  • Buethe DD, Pow-Sang J. Enrollment criteria controversies for active surveillance and triggers for conversion to treatment in prostate cancer. J Natl Compr Canc Netw. 2012 Sep;10(9):1101-1110. Pubmedid: 22956809.

  • Rivers BM, August EM, Quinn GP, Gwede CK, Pow-Sang JM, Green BL, Jacobsen PB. Understanding the Psychosocial Issues of African American Couples Surviving Prostate Cancer. J Cancer Educ. 2012 Jun;27(3):546-558. Pubmedid: 22544536.

  • Finkelstein SE, Rodriguez F, Dunn M, Farmello MJ, Smilee R, Janssen W, Kang L, Chuang T, Seigne J, Pow-Sang J, Torres-Roca JF, Heysek R, Biagoli M, Shankar R, Scott J, Antonia S, Gabrilovich D, Fishman M. Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy. Immunotherapy. 2012 Apr;4(4):373-382. Pubmedid: 22512631. Pmcid: PMC4241355.

  • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Slaton J, Anderson JK. Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. Contemp Clin Trials. 2012 Mar;33(2):279-285. Pubmedid: 22101219. Pmcid: PMC3268882.

  • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Connors S, Chornukur G, Dickinson SI, Bai W, Williams CR, Salup R, Fu W. Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures. J Cancer Sci Ther. 2012 Jan;2011(S3). Pubmedid: 22422102.

  • Kumar N, Crocker T, Smith T, Connors S, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Anderson K. Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. J Clin Trials. 2012 Jan;2(1). Pubmedid: 24533253. Pmcid: PMC3924733.

  • Lin HY, Park HY, Radlein S, Mahajan NP, Sellers TA, Zachariah B, Pow-Sang J, Coppola D, Ganapathy V, Park JY. Protein expressions and genetic variations of SLC5A8 in prostate cancer risk and aggressiveness. Urology. 2011 Oct;78(4):971.e1-971.e9. Pubmedid: 21802122. Pmcid: PMC3190039.

  • Ercole CE, Pow-Sang JM, Spiess PE. Update in the surgical principles and therapeutic outcomes of inguinal lymph node dissection for penile cancer. Urol Oncol. 2011 Apr;31(5):505-516. Pubmedid: 21481617.

  • Pow-Sang JM. Editorial comment. Urology. 2011 Feb;77(2):367. Pubmedid: 21295251.

  • Rivers BM, August EM, Gwede CK, Hart A, Donovan KA, Pow-Sang JM, Quinn GP. Psychosocial issues related to sexual functioning among African-American prostate cancer survivors and their spouses. Psychooncology. 2011 Jan;20(1):106-110. Pubmedid: 20187071.

  • Kolla SB, Ercole C, Spiess PE, Pow-Sang JM, Sexton WJ. Nephron-sparing surgery for pathological stage T3b renal cell carcinoma confined to the renal vein. BJU Int. 2010 Nov;106(10):1494-1498. Pubmedid: 20230378.

  • Correa JJ, Pow-Sang JM. Optimizing cancer control and functional outcomes following robotic prostatectomy. Cancer Control. 2010 Oct;17(4):233-244. Pubmedid: 20861811.

  • Pow-Sang JM. Progress in treatment of genitourinary malignancies. Cancer Control. 2010 Oct;17(4):212. Pubmedid: 20861808.

  • Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010 Feb;8(2):162-200. Pubmedid: 20141676.

  • Ignatoff JM, Chen YH, Greenberg RE, Pow-Sang JM, Messing EM, Wilding G. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group. Urol Oncol. 2009 Nov;27(5):496-501. Pubmedid: 18639470. Pmcid: PMC2743955.

  • Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, Ostrander EA, Ingles SA, John EM, Thibodeau SN, Schaid D, Park JY, Spurdle A, Clements J, Dickinson JL, Maier C, Vogel W, D?rk T, Rebbeck TR, Cooney KA, Cannon-Albright L, Chappuis PO, Hutter P, Zeegers M, Kaneva R, Zhang HW, Lu YJ, Foulkes WD, English DR, Leongamornlert DA, Tymrakiewicz M, Morrison J, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Saunders EJ, Page EC, Sawyer EJ, Edwards SM, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Southey MC, Lophatananon A, Liu JF, Kolonel LN, Le Marchand L, Wahlfors T, Tammela TL, Auvinen A, Lewis SJ, Cox A, FitzGerald LM, Koopmeiners JS, Karyadi DM, Kwon EM, Stern MC, Corral R, Joshi AD, Shahabi A, McDonnell SK, Sellers TA, Pow-Sang J, Chambers S, Aitken J, Gardiner RA, Batra J, Kedda MA, Lose F, Polanowski A, Patterson B, Serth J, Meyer A, Luedeke M, Stefflova K, Ray AM, Lange EM, Farnham J, Khan H, Slavov C, Mitkova A, Cao G, Easton DF. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genetics. 2009 Oct;41(10):1116-1121. Pubmedid: 19767753. Pmcid: PMC2846760.

  • Caso J, Seigne J, Back M, Spiess PE, Pow-Sang J, Sexton WJ. Circumferential resection of the inferior vena cava for primary and recurrent malignant tumors. J Urol. 2009 Sep;182(3):887-893. Pubmedid: 19616230.

  • Coppola D, Oliveri C, Sayegh Z, Boulware D, Takahashi Y, Pow-Sang J, Djeu JY, Wang HG. Bax-interacting factor-1 expression in prostate cancer. Clin Genitourin Cancer. 2008 Sep;6(2):117-121. Pubmedid: 18824435. Pmcid: PMC2626142.

  • Fishman M, Hunter T, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo M, Noyes D, Mahany J, Lee J, Cantor A, Messina J, Seigne J, Pow-Sang J, JanssenW, Antonia S. Phase II Trial of B7-1 (CD-86) Transduced, Cultured Autologous Tumor Cell Vaccine Plus Subcutaneous Interleukin-2 for Treatment of Stage IV Renal Cell Carcinoma. J Immunother (1997). 2008 Jan;31(1):72-80. Pubmedid: 18157014.

  • Pow-Sang J. Pure and robotic-assisted laparoscopic radical prostatectomy: technology and techniques merge to improve outcomes. Expert Rev Anticancer Ther. 2008 Jan;8(1):15-19. Pubmedid: 18095879.

  • Park J, Zheng W, Kim D, Cheng J, Kumar N, Ahmad N, Pow-Sang J. Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detect Prev. 2007 Nov;31(5):359-365. Pubmedid: 18037591.

  • Barnholtz-Sloan J, Maldonado J, Pow-Sang J, Giuliano A. Incidence trends in primary malignant penile cancer. Urol Oncol. 2007 Sep;25(5):361-367. Pubmedid: 17826651.

  • Mohler J, Babaian R, Bahnson R, Boston B, D'Amico A, Eastham J, Hauke R, Huben R, Kantoff P, Kawachi M, Kuettel M, Lange P, Logothetis C, MacVicar G, Pollack A, Pow-Sang J, Roach M 3rd, Sandler H, Shrieve D, Srinivas S, TwardowskiP, Urban D, Walsh P. Prostate cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Aug;5(7):650-683. Pubmedid: 17692170.

  • Park J, Tanner J, Sellers T, Huang Y, Stevens C, Dossett N, Shankar R, Zachariah B, Heysek R, Pow-Sang J. Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk. Urology. 2007 Aug;70(2):374-379. Pubmedid: 17826523.

  • Pow-Sang J, Velasquez J, Myers M, Rodriguez A, Kang L. Pure laparoscopic and robotic-assisted laparoscopic radical prostatectomy in the management of prostate cancer. Cancer Control. 2007 Jul;14(3):250-257. Pubmedid: 17615531.

  • Correa J, Politis C, Rodriguez A, Pow-Sang J. Laparoscopic retroperitoneal lymph node dissection in the management of testis cancer. Cancer Control. 2007 Jul;14(3):258-264. Pubmedid: 17615532.

  • Rodriguez A, Kapoor R, Pow-Sang J. Laparoscopic extraperitoneal radical prostatectomy in complex surgical cases. J Urol. 2007 May;177(5):1765-1770. Pubmedid: 17437812.

  • Kumar NB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, Kang L, Xu P, Pow-Sang J. A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer. 2007;59(2):163-168. Pubmedid: 18001210. Pmcid: PMC2435485.

  • Kumar NBB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, Kang L, Xu P, Pow-Sang J. Safety of purified isoflavones in men with clinically localized prostate cancer. Nutr Cancer. 2007;59(2):169-175. Pubmedid: 18001211. Pmcid: PMC2442460.

  • Patterson S, Wei S, Chen X, Sallman D, Gilvary D, Zhong B, Pow-Sang J, Yeatman T, Djeu J. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene. 2006 Nov;25(45):6113-6122. Pubmedid: 16652143.

  • Torres-Roca J, Cantor A, Shukla S, Montejo M, Friedland J, Seigne J, Heysek R, Pow-Sang J. Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: a review of the H. Lee Moffitt Cancer Center experience. Urol Oncol. 2006 Oct;24(5):384-390. Pubmedid: 16962486.

  • Rodriguez A, Pow-Sang J. Laparoscopic surgery in urologic oncology. Cancer Control. 2006 Jul;13(3):169-178. Pubmedid: 16885912.

  • Rodriguez A, Kang L, Politis C, Wade M, Sexton W, Miranda-Sousa A, Pow-Sang JM. Delayed metastatic renal carcinoma to prostate. Urology. 2006 Mar;67(3):623-623. Pubmedid: 16527593.

  • Chen L, Ambrosone CB, Lee J, Sellers TA, Pow-Sang J, Park JY. Association between polymorphisms in the DNA repair genes XRCC1 and APE1, and the risk of prostate cancer in white and black Americans. J Urol. 2006 Jan;175(1):108-112. Pubmedid: 16406883.

  • Pow-Sang J. Uro-oncology: improved techniques produce better outcomes. Cancer Control. 2006;13(3):156-156. Pubmedid: 16885910.

  • Gwede C, Pow-Sang J, Seigne J, Heysek R, Helal M, Shade K, Cantor A, Jacobsen P. Treatment decision-making strategies and influences in patients with localized prostate carcinoma. Cancer. 2005 Oct;104(7):1381-1390. Pubmedid: 16080181.

  • Rodriguez A, Burday D, Sexton W, Ahmad N, Pow-Sang J. Urothelial carcinoma in a child. Arch Esp Urol. 2005 Jun;58(5):473-475. Pubmedid: 16078794.

  • Kumar N, Cantor A, Allen K, Riccardi D, Besterman-Dahan K, Seigne J, Helal M, Salup R, Pow-Sang J. The specific role of isoflavones in reducing prostate cancer risk. Prostate. 2004 May;59(2):141-147. Pubmedid: 15042614.

  • Moreira S, Seigne J, Ordorica R, Marcet J, Pow-Sang J, Lockhart J. Devastating complications after brachytherapy in the treatment of prostate adenocarcinoma. Bju Int. 2004;93(1):31-35. Pubmedid: 14678363.

  • Park J, Chen L, Shade K, Lazarus P, Seigne J, Patterson S, Helal M, Pow-Sang J. Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer. J Urol. 2004;171(6Pt1):2484-2488. Pubmedid: 15126881.

  • Pow-Sang J. Genitourinary oncology: the continuous evolution of multimodality treatments. Cancer Control. 2004;11(6):351-351. Pubmedid: 15625521.

  • Vadaparampil S, Jacobsen P, Kash K, Watson I, Saloup R, Pow-Sang J. Factors predicting prostate specific antigen testing among first-degree relatives of prostate cancer patients. Cancer Epidemiol Biomarkers Prev. 2004;13(5):753-758. Pubmedid: 15159306.

  • Jacobsen P, Lamonde L, Honour M, Kash K, Hudson P, Pow-Sang J. Relation of family history of prostate cancer to perceived vulnerability and screening behavior. Psychooncology. 2004;13(2):80-85. Pubmedid: 14872526.

  • Keehn C, Pow-Sang J, Ahmad N. Pathologic quiz case: a 57-year-old man with hypertension and hypokalemia. Arch Pathol Lab Med. 2003 Apr;127(4):495-496. Pubmedid: 12683884.

  • Webster C, Bukkapatnam R, Seigne J, Pow-Sang J, Hoffman M, Helal M, Ordorica R, Lockhart J. Continent colonic urinary reservoir (Florida pouch): long-term surgical complications (greater than 11 years). J Urol. 2003;169(1):174-176. Pubmedid: 12478129.

  • Thurman S, Robinson L, Ahmad N, Pow-Sang J, Lockhart J, Seigne J. Investigation of the safety and accuracy of intraoperative gamma probe directed biopsy of bone scan detected rib abnormalities in prostatic adenocarcinoma. J Urol. 2003;169(4):1341-1344. Pubmedid: 12629356.

  • Shukla A, Pow-Sang J, Helal M, Seigne J, Ordorica R, Lockhart J. Urinary incontinence after continent urinary diversion using cecal wrap or plicated ileum: a patient questionnaire review. Urology. 2003;61(2):328-331. Pubmedid: 12597940.

  • Chen L, Elahi A, Pow-Sang J, Lazarus P, Park J. Association between polymorphism of human oxoguanine glycosylase 1 (hOGG1) and risk for prostate cancer. J Urol. 2003;170(6 Pt1):2471-2474. Pubmedid: 14634453.

  • Pow-Sang J. The spectrum of genitourinary malignancies. Cancer Control. 2002;9(4):275-276. Pubmedid: 12228752.

  • Antonia S, Seigne J, Diaz J, Muro-Cacho C, Extermann M, Farmelo M, Friberg M, Alsarraj M, Mahany J, Pow-Sang J, Cantor A, Janssen W. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol. 2002;167(5):1995-2000. Pubmedid: 11956426.

  • Mora L, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, FalconeR, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J, Jove R. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002;62(22):6659-6666. Pubmedid: 12438264.

  • Moreira SG J, Pow-Sang J. Evaluation and management of adrenal masses. Cancer Control. 2002;9(4):326-334. Pubmedid: 12228758.

  • Patterson S, Balducci L, Pow-Sang J. Controversies surrounding androgen deprivation for prostate cancer. Cancer Control. 2002;9(4):315-325. Pubmedid: 12228757.

  • Pow-Sang M, Benavente V, Pow-Sang J, Morante C, Meza L, Baker M, Pow-Sang JM. Cancer of the penis. Cancer Control. 2002;9(4):305-314. Pubmedid: 12228756.

  • Pow-Sang J. Prostate cancer at the beginning of the 21st century: more options and better outcomes. Cancer Control. 2001 Nov;8(6):480-481. Pubmedid: 11807417.

  • Pow-Sang J. Clinically localized prostate cancer: the paradox of paradoxes. Cancer Control. 2001;8(2):126-126. Pubmedid: 11326166.

  • Bukkapatnam R, Pow-Sang J. Radical prostatectomy in the management of clinically localized prostate cancer. Cancer Control. 2001;8(6):496-502. Pubmedid: 11807419.

  • Hoff B, Pow-Sang J. Observation in the management of localized prostate cancer. Cancer Control. 2001;8(2):151-154. Pubmedid: 11326169.

  • Pow-Sang J. Bladder cancer: one enemy, many fronts. Cancer Control. 2000 Jul;7(4):307-307. Pubmedid: 10895125.

  • Diaz J, Pow-Sang J, Mora L, Seigne J, Cantor A, Dalton W. Cytometric analysis of Fas and Bcl-2 expression in normal prostatic epithelium and prostate cancer. Urol Oncol. 2000;5(4):149-154. Pubmedid: 10869956.

  • Diaz J, Mora L, Austin P, Muro-Cacho C, Cantor A, Nicosia S, Pow-Sang J. Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation. Urology. 1999;53(5):931-938. Pubmedid: 10223486.

  • Seigne J, Turner J, Diaz J, Hackney J, Pow-Sang J, Helal M, Lockhart J, Yu H. A feasiblity study of gene gun mediated immunotherapy for renal cell carcinoma. J Urol. 1999;162(4):1259-1263. Pubmedid: 10492175.

  • Feygelman V, Pow-Sang J, Friedland J, Sanders R. Needle imaging during ultrasound-guided permanent prostate implants. Tech Urol. 1999;3:143-145. Pubmedid: noPMID.

  • Pow-Sang J. Just the facts, ma'am. Cancer Control. 1999;6(6):545-546. Pubmedid: 10756385.

  • Chabarek N, Mora L, Diaz J, Pow-Sang J. La edad como factor de riesgo de complicaciones post-operatorias en prostatectomia radical retropubica. Urologia Panamericana. 1999;11(3):17-19. Pubmedid: noPMID.

  • Pow-Sang J, Friedland J, Seigne J, Feygelman V. Brachytherapy for prostate cancer. Urologia Panamericana. 1999;11(4):24-26. Pubmedid: noPMID.

  • Pow-Sang J. The best readings on genitourinary tumors. (Editorial). Cancer Control. 1999;6(6):594-595. Pubmedid: noPMID.

  • Mora L, Moscinski L, Diaz J, Blair P, Cantor A, Pow-Sang J. Stage B prostate cancer: correlation of DNA ploidy analysis with histological and clinical parameters. Cancer Control. 1999;6(6):587-591. Pubmedid: 10756390.

  • Masel J, Austin P, Spyropoulos E, Seigne J, Pow-Sang J, Odorica R, Lockhart J. Enterocystometric comparison of plicated ileocecal segment (PI) and flap valve (IV) continence mechanisms in the Florida pouch. Urology. 1999;53(3):506-509. Pubmedid: 10096375.

  • Lynch C, Towsley G, Pow-Sang J, Lockhart J, Seigne J. Long-term urodynamic changes of a continent colonic urinary reservoir. J Pelvic Surgeons. 1999;5(1):13-16. Pubmedid: noPMID.

  • Pow-Sang J. Prostate cancer: of turtles, birds, and rabbits. Cancer Control. 1998;5(6):483-484. Pubmedid: 10761096.

  • Pow-Sang J. Ten best readings on prostate cancer. Cancer Control. 1998;5(6):559-560. Pubmedid: noPMID.

  • Lynch C, Towsley G, Pow-Sang J, Lockhart J. Long-term urodynamic evaluation of a continent urinary reservoir. Prim Care Update Ob Gyns. 1998;5(4):200-200. Pubmedid: 10838382.

  • Benson K, Agosti S, Lyman G, Pow-Sang J, Saba H, Balducci L. Estimated blood loss in group O as compared to non-group O radical prostatectomy. Hematology. 1998;3:257-261. Pubmedid: noPMID.

  • Helal M, Austin P, Spyropoulos E, Pow-Sang J, Persky L, Lockhart J. Evaluation and management of parastomal hernia in association with continent urinary diversion. J Urol. 1997;157:1630-1632. Pubmedid: 9112492.

  • Pow-Sang J. Genitourinary cancers:update on detection, treatment, and research. Cancer Control. 1996;6(3):486-487.

  • Mora L, Nicosia S, Pow-Sang J, Ku N, Diaz J, Lockhart J, Einstein, Jr. A. Ancillary techniques in the follow-up of trasitional cell carcinoma: a comparision of cytology, histology and DNA image analysis cytometry in 91 patients. J Urol. 1996;156:49-55. Pubmedid: 8648836.

  • Pow-Sang J, Marshburn J. Prostate cancer clinical guidelines. Cancer Control. 1996;6(3):526-627. Pubmedid: 10764513.

  • Diaz J, Nicosia S, Szakacs J, Pow-Sang J, Saba H. Metastatic Seminoma Simulating Malignant lymphoma in an HIV infected hemophiliac. Leuk Lymphoma. 1996;23:165-171. Pubmedid: 9021701.

  • Rabb H, Borrasa E, Adams R, Pow-Sang J, Ramirez G. Alpha-v/beta-3 and alpha-5/beta-3 integrin expression in cancerous kidney. Am J Nephrol. 1996;16:402-402. Pubmedid: 8886177.

  • Pow-Sang J, Spyropoulos E, Helal M, Lockhart J. Bladder replacement and urinary diversion after radical cystectomy. Cancer Control. 1996;3(6):512-518. Pubmedid: 10764510.

  • Pow-Sang J. Ten best readings. Cancer Control. 1996;3(3):542-543.

  • Horton J, Pow-Sang J. Continuing medical education. Cancer Control. 1995;2(1):77-81. Pubmedid: noPMID.

  • Pow-Sang J. Prostate cancer: detection and management. Cancer Control. 1995;1(2):9-9. Pubmedid: 10887390.

  • Friedland J, Pow-Sang J, Johnson D, Byrnes J. Quality of life issues associated with the treatment of prostate cancer. Cancer Control. 1995;2(1):42-46. Pubmedid: 10887396.

  • Pow-Sang J. Contoversias en el manejo de cancer de rinon. Urologia Panamericana. 1995;7:41-46. Pubmedid: noPMID.

  • Pow-Sang J. Ten best readings in prostate cancer. Cancer Control. 1995;1(2):62-63. Pubmedid: noPMID.

  • Pow-Sang J. Carta del editor invitado. Urologia Panamericana. 1995;7:1-2. Pubmedid: noPMID.

  • Diaz J, Nicosia S, Szakacs J, Pow-Sang J, Saba H. Metastatic seminoma simulating malignant lymphoma in an HIV infected hemophiliac. Leuk Lymphoma. 1995;18:179-184. Pubmedid: noPMID.

  • Helal M, Figueroa T, Pow-Sang J, Sanford E, Lockhart J. A trans-reservoir technique for correction of ureterointestinal obstruction in continenta urinary diversion. J Urol. 1995;153:1108-1109. Pubmedid: 7869474.

  • Greene J, Sandin R, Fields K, Moscinski L, Beatty A, Pow-Sang J, Elfenbein G. Hemorrhagic cystitis in bone marrow transplant patients: is it an infection or chemotherapy toxicity?. Cancer Control. 1994;1(4):411-415.

  • Szakacs J, Pow-Sang J. The pathologist's role in multidisciplinary management of bladder cancer. Ann Clin Lab Sc. 1994;24(6):481-488.

  • Shabaik A, Pow-Sang J, Lockhart J, Nicosia S. Role of DNA image cytometry in the follow-up of patients with urinary tract transitional cell carcinoma. Anal Quant Cytol Histol. 1993 Apr;15(2):115-123. Pubmedid: 8318126.

  • Helal M, Pow-Sang J, Sanford E, Figueroa T, Lockhart J. Direct (non-tunnelled) uretero-colonic reimplantation in association with continent reservoirs. J Urol. 1993;150:835-837.

  • Katz M, Sanford E, Valle J, Lowe D, Pow-Sang J, Braman R. 1993;240A.

  • Gray G, Hernandez O, Hebel D, Root M, Pow-Sang J. Antisense DNA inhibition of HA-RAS induced tumor growth in nude mice. Cancer Res. 1993;53:577-580.

  • Pow-Sang J, Lockhart J. Continent urinary diversion: the Florida pouch. Problems In Urology. 1992;6(3):581-586.

  • Pow-Sang J, Helal M, Figueroa E, Sanford E, Persky L, Lockhart J. Conversion from external appliance wearing or internal urinary diversion to a continent urinary reservoir (Florida pouch I and II): surgical technique, indications and complications. J Urol. 1992;147:356-360.

  • Pow-Sang J, Lockhart J, Helal M, Persky L, Sanford E. The Florida pouch: diversion to minimize obstruction. Contemp Urol. 1992;4(2):20-29.

  • Lockhart J, Pow-Sang J, Persky L, Sanford E. The Florida pouch: a simplified technique for continent urinary diversion. Urologia Panamericana. 1990;2(1):33-39.

  • Lockhart J, Pow-Sang J, Persky L, Kahn P, Vorstman B, Ellis G, Helal M. Detivacao urinaria continente desenvolvida na Florida: uma te cnica para a America Latina. J Bras Urol. 1989;15:115-115.

  • Heysek R, Gwede C, Torres-Roca J, Cantor A, Kelley S, Saini A, Pow-Sang J. A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy. Brachytherapy. 5(4):244-250. Pubmedid: 17118318.

  • Rodriguez AR, Rachna K, Pow-Sang JM. Laparoscopic extraperitoneal radical prostatectomy: impact of the learning curve on perioperative outcomes and margin status. JSLS. 14(1):6-13. Pubmedid: 20529523. Pmcid: PMC3021300.

  • Pow-Sang J, Seigne J. Contemporary management of superficial bladder cancer. Cancer Control. 7(4):335-339. Pubmedid: 10895127.

  • Kumar NB, Kang L, Pow-Sang J, Xu P, Allen K, Riccardi D, Besterman-Dahan K, Krischer JP. Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy. J Soc Integr Oncol. 2010 Winter;8(1):3-13. Pubmedid: 20205984.

  • Pow-Sang J, Pow-Sang J. Tratado De Urologia Oncologica. 1997.

  • Balducci L, Pow-Sang J, Friedland J, Diaz J. Cancer in the elderly part II: prostate cancer. In: Balducci L, ed. Clinics in geriatric medicine. Philadelphia, PA: Saunders; 1997;283-306.

  • Torres-Roca JF, Cantor AB, Shukla S, Montejo ME, Friedland J, Seigne JD, Heysek R, Heysek, Randy, Pow-Sang J. Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: a review of the H. Lee Moffitt Cancer Center experience. Urol Oncol. 2006 Sept - Oct;24(5):384-390.

  • Feygelman V, Friedland J, Sanders R, Noriega B, Pow-Sang J. Improvement in dosimetry of ultrasound-guided prostate implants with the use of multiple stabilization needles. Med Dosim. 1996 Sum;21(2):109-112. Pubmedid: 8807612 .

  • Pow-Sang J, Friedland J, Einstein, Jr. A. Transitional carcinoma of the bladder in the elderly. In: Comprehensive Geriatric Oncology. London. Harwood Academic Publishers; 1998;697-702.

  • Pow-Sang J, Pow-Sang J. Manual De Urologia, Primera Edicion. Lima, Peru. Editorial Piramide; 1996.

Dr. Julio Pow-Sang is chairman of genitourinary oncology at Moffitt Cancer Center, as well as chief of surgery and director of the robotics program.  He is certified in robotic laparoscopic surgery and is a professor of surgery and oncology at the University of South Florida College of Medicine. 

A native of Peru, Dr. Pow-Sang received his medical degree from the Universidad Autonoma de Guadalajara in Mexico.  He completed residencies in surgery and urology at the University of Miami School of Medicine and a fellowship in urological oncology at the University of Florida in Gainesville.

Dr. Pow-Sang is a principal investigator for numerous clinical trials in genitourinary cancer and is a member of the prostate cancer guidelines panel for the National Comprehensive Cancer Network.  In addition, he is on the editorial board and a reviewer for many professional journals, as well as a member of professional medical societies in the U.S., Europe and Peru.

In addition to his medical studies, Dr. Pow-Sang has a master’s in business administration from the University of South Florida.  He is a diplomate of the American Board of Managed Care Medicine.

Dr. Pow-Sang is fluent in English, Spanish and French, and speaks conversational German and Italian.   He has been named one of the Best Doctors in America since 1998.


TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions